Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.RNTX · Entity 7071 | Director · See Remarks | April 30, 2026 | May 13, 2026 |
| TFF Pharmaceuticals, Inc.TFFP · Entity 89110 | Director · Chief Science Officer | December 07, 2020 | December 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date April 30, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock , $0.001 par valueSEC Table I · non-derivative | Direct | 27,046 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Purchase · Acquired 25,000 · Balance 27,046 F1: Shares purchased in Issuer's April 30, 2026 follow-on public offering. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2036-05-08 | Direct | 150,000 |
Reported balance
After 2026-05-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-08 · Grant · Disposed 150,000 · Balance 150,000 F2: This option was granted on May 8, 2026. The 25% of the shares underlying the option are scheduled to vest on May 8, 2027 and thereafter in equal monthly installments through May 8, 2031. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased in Issuer's April 30, 2026 follow-on public offering.
F2: This option was granted on May 8, 2026. The 25% of the shares underlying the option are scheduled to vest on May 8, 2027 and thereafter in equal monthly installments through May 8, 2031.
TFF Pharmaceuticals, Inc.
Report date December 07, 2020 · Filed December 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Ending reported balance
After 2020-12-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-07 · Exercise / conversion · Acquired 25,000 · Balance 30,000 F1: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. Row 2 · 2020-12-07 · Sale · Disposed 25,000 · Balance 5,000 F1: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-09-26 | Direct | 134,429 |
Reported balance
After 2020-12-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-07 · Exercise / conversion · Disposed 25,000 · Balance 134,429 F1: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. F2: 18,003 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 4,500 every three months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
F2: 18,003 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 4,500 every three months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 13, 2026 12:47 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001193125-26-220718 · ownership.xml · derivative · entry 2 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-05-08 F2 · derivative.exercise_date: This option was granted on May 8, 2026. The 25% of the shares underlying the option are scheduled to vest on May 8, 2027 and thereafter in equal monthly installments through May 8, 2031. Read SEC document |
| April 30, 2026 Filed May 13, 2026 12:47 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | PurchaseCommon stock , $0.001 par value | 25,000 | $1.00 | $25,000.00 |
DisclosureSEC source: 0001193125-26-220718 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,046 F1 · shares: Shares purchased in Issuer's April 30, 2026 follow-on public offering. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 21:09 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 161 | $2.25 | $362.25 |
DisclosureSEC source: 0000950170-24-134522 · ownership.xml · nonDerivative · entry 2 WINDSOR JAMES BRIAN · CIK 0001790933 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By son Disclosed balance after: 161 F1 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 21:09 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 239 | $2.24 | $535.36 |
DisclosureSEC source: 0000950170-24-134522 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By son Disclosed balance after: 239 F1 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:05 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 517,500 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000950170-24-133231 · ownership.xml · derivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,500 Underlying: Common Stock · 517,500 shares Expires 2034-12-01 F1 · derivative.exercise_date: This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest as of 25% of the shares on December 2, 2025 and thereafter in equal monthly installments through December 2, 2028. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 22:06 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | Exercise / conversionSeries X Non-Voting Convertible Preferred · Derivative | 2 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027304 · ownership.xml · derivative · entry 3 WINDSOR JAMES BRIAN · CIK 0001790933 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · price: On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · derivative.exercise_date: On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. F1 · derivative.expiration_date: On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 22:06 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027304 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 22:56 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 225 | $3.37 | $758.25 |
DisclosureSEC source: 0000950170-23-071200 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · President and COO 10b5-1 filing: No plan indicated Ownership: Indirect · By son Disclosed balance after: 225 F1 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 21:43 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 5,076 | $1.97 | $9,987.03 |
DisclosureSEC source: 0000950170-23-065545 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,122 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.965 - $1.9699. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:30 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001213900-20-041813 · ownership.xml · derivative · entry 3 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,429 Underlying: Common Stock · 25,000 shares Expires 2028-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. F2 · derivative.exercise_date: 18,003 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 4,500 every three months thereafter. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:30 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | SaleCommon Stock | 25,000 | $15.80 | $395,000.00 |
DisclosureSEC source: 0001213900-20-041813 · ownership.xml · nonDerivative · entry 2 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 16:30 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | Exercise / conversionCommon Stock | 25,000 | $2.50 | $62,500.00 |
DisclosureSEC source: 0001213900-20-041813 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 18:13 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001213900-20-023891 · ownership.xml · derivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,429 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021. F1 · derivative.expiration_date: Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 19:44 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 3,623 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-19-025253 · ownership.xml · derivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,429 Underlying: Common Stock · 3,623 shares Expires 2029-10-29 F1 · derivative.exercise_date: 25% of the options vest on the first anniversary of the grant and the remainder vest in equal quarterly installments over the next three years. Read SEC document |
| October 29, 2019 Filed Oct 29, 2019 20:35 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 43,794 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-19-021428 · ownership.xml · derivative · entry 2 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,806 Underlying: Common Stock · 43,794 shares Expires 2029-10-29 F2 · derivative.exercise_date: 25% of the options vest on the first anniversary of the grant and the remainder vest in equal quarterly installments over the next three years. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:35 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | PurchaseCommon Stock | 5,000 | $5.00 | $25,000.00 |
DisclosureSEC source: 0001213900-19-021428 · ownership.xml · nonDerivative · entry 1 WINDSOR JAMES BRIAN · CIK 0001790933 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The shares of common stock purchased in the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.